about
Crosstalk and Interplay between the Ubiquitin-Proteasome System and Autophagy.Topotecan is a potent inhibitor of SUMOylation in glioblastoma multiforme and alters both cellular replication and metabolic programming.Src SUMOylation Inhibits Tumor Growth Via Decreasing FAK Y925 Phosphorylation.The SUMO guards for SNAIL.Protein SUMOylation modification and its associations with disease.Shigella entry unveils a calcium/calpain-dependent mechanism for inhibiting sumoylation.Ubiquitin signaling and autophagy.SUMO2/3 modification of activating transcription factor 5 (ATF5) controls its dynamic translocation at the centrosome.Pathways from senescence to melanoma: focus on MITF sumoylation.Quantitative high-throughput screening identifies cytoprotective molecules that enhance SUMO conjugation via the inhibition of SUMO-specific protease (SENP)2.Assessing predictions of fitness effects of missense mutations in SUMO-conjugating enzyme UBE2I.Akt Protein Kinase, miR-200/miR-182 Expression and Epithelial-Mesenchymal Transition Proteins in Hibernating Ground Squirrels.N-terminal Sumoylation of Centromeric Histone H3 Variant Cse4 Regulates Its Proteolysis To Prevent Mislocalization to Non-centromeric Chromatin.Ginkgolic acid, a sumoylation inhibitor, promotes adipocyte commitment but suppresses adipocyte terminal differentiation of mouse bone marrow stromal cells.Arsenic and SUMO wrestling in protein modification.SUMOylation of the m6A-RNA methyltransferase METTL3 modulates its function.The Biology of SUMO-Targeted Ubiquitin Ligases in Drosophila Development, Immunity, and Cancer.The post-translational modification, SUMOylation, and cancer (Review).Site-specific characterization of endogenous SUMOylation across species and organs.The SUMO System and TGFβ Signaling Interplay in Regulation of Epithelial-Mesenchymal Transition: Implications for Cancer ProgressionSUMO-Mediated Regulation of Nuclear Functions and Signaling ProcessesPIAS1 protects against myocardial ischemia-reperfusion injury by stimulating PPARγ SUMOylation
P2860
Q39457805-6B46E8A4-8D9E-4200-B66A-3CFAA3F51533Q41287854-6F847629-AD90-48A6-AE33-E54DC0B082D6Q42648308-719039BE-7E03-43C5-8F49-16A3F3C7474FQ46931128-6F1BEE31-8221-43D2-B168-33C038698BE8Q47099041-8E112434-ED5E-439E-AEC5-1382D1883221Q47324931-E259B970-ED43-4F1D-9396-3EE2A3B88A73Q47349935-C71AAC37-4370-4EA1-A204-D4F7CFE90AC9Q47554901-0577201B-5363-4B20-BB8C-31FFD46EF19BQ47927484-663877A2-F773-4763-AD80-09EE6C7AD6EAQ47965761-4FDE587F-C1E2-4B56-A594-86CA1F92FD74Q48222762-C4A54231-B2AE-48D9-8636-84F628D8CFC4Q49395543-34AB30A2-BE63-4DBD-B8A7-274B0C1DCAC2Q50064002-341AD8BB-45FB-4F66-BE0E-5E3C91984676Q50130005-92ABBBA2-9209-4ACD-A30B-426D3F37DC23Q51026375-F2FA8D4A-44EB-4463-9504-9B192CADBF16Q52367004-63E5B3EB-E591-48E4-9719-920EF8EEFFFFQ52721924-EC4DB418-BF4E-44E9-AC70-7EAA40F66F61Q52730181-8FA6E3E6-107F-49A1-BC53-3F93E9ED203DQ55320105-23D582B5-0BF2-473F-88CB-444882D47731Q58795170-0F6B8558-A73C-4DA3-8088-C674631C8B1BQ58803049-5C0668AE-6A69-4F0D-9E4B-87870EC5B584Q59127320-20288338-BDBD-448A-ADB9-3F55360AEAF6
P2860
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
SUMO and the robustness of cancer.
@en
SUMO and the robustness of cancer.
@nl
type
label
SUMO and the robustness of cancer.
@en
SUMO and the robustness of cancer.
@nl
prefLabel
SUMO and the robustness of cancer.
@en
SUMO and the robustness of cancer.
@nl
P2860
P356
P1476
SUMO and the robustness of cancer.
@en
P2093
Jacob-Sebastian Seeler
P2860
P2888
P304
P356
10.1038/NRC.2016.143
P407
P577
2017-01-30T00:00:00Z
P6179
1074247028